31 related articles for article (PubMed ID: 10587312)
1. Preparation and Preliminary Structure-Activity Relationship Studies of Schwarzinicine A Analogs as Vasorelaxant Agents.
Lee FK; Chan NJ; Krishnan P; Datu Abdul Salam DS; Chee XW; Muhamad A; Low YY; Ting KN; Lim KH
J Nat Prod; 2024 Apr; 87(4):675-691. PubMed ID: 38442031
[TBL] [Abstract][Full Text] [Related]
2. Total Synthesis and Conformational Analysis of Naturally Occurring Lipovelutibols along with Lead Optimization of Lipovelutibol D.
Singh VP; Pathania AS; Sharma S; Malik FA; Kumar A; Singh D; Vishwakarma RA
ACS Omega; 2021 Mar; 6(9):6070-6080. PubMed ID: 33718698
[TBL] [Abstract][Full Text] [Related]
3. Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions.
Gokula V; Terrero D; Joe B
Curr Hypertens Rep; 2022 Dec; 24(12):669-685. PubMed ID: 36301488
[TBL] [Abstract][Full Text] [Related]
4. A comparison between haemodynamic effects of vasopressin analogues.
Tabrizchi R; Ford CA
Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov; 370(5):340-6. PubMed ID: 15526109
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
Stoev S; Cheng LL; Manning M; Wo NC; Szeto HH
J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
[TBL] [Abstract][Full Text] [Related]
6. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
7. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
8. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
9. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
[TBL] [Abstract][Full Text] [Related]
11. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
Chan WY; Wo NC; Stoev ST; Cheng LL; Manning M
Exp Physiol; 2000 Mar; 85 Spec No():7S-18S. PubMed ID: 10795902
[TBL] [Abstract][Full Text] [Related]
12. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
